Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses

Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma

(2015) Mehrdad Talebian Yazdi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer

(2015) Eveline M. Dijkgraaf et al.   Oncotarget

Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death

(2014) T. C. van der Sluis et al.   CLINICAL CANCER RESEARCH

A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer

(2014) Domenica Lorusso et al.   GYNECOLOGIC ONCOLOGY

HPV16-associated tumors control myeloid cell homeostasis in lymphoid organs, generating a suppressor environment for T cells

(2014) Simone Cardozo Stone et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer

(2014) MCA Wouters et al.   OncoImmunology

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

(2013) L Bracci et al.   CELL DEATH AND DIFFERENTIATION

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

(2013) Mariette I E van Poelgeest et al.   Journal of Translational Medicine

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response

(2012) Y. Diaz et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

Therapeutic vaccination against human papilloma virus induced malignancies

(2011) Sjoerd H van der Burg et al.   CURRENT OPINION IN IMMUNOLOGY

Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer

(2011) Seiji Mabuchi et al.   GYNECOLOGIC ONCOLOGY

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

(2010) M. J. P. Welters et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy

(2009) Xia Wu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

(2009) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

(2009) Gemma G. Kenter et al.   NEW ENGLAND JOURNAL OF MEDICINE